1. Home
  2. AEHL vs LYRA Comparison

AEHL vs LYRA Comparison

Compare AEHL & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEHL

Antelope Enterprise Holdings Limited

HOLD

Current Price

$0.94

Market Cap

6.2M

Sector

Industrials

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEHL
LYRA
Founded
1993
2005
Country
China
United States
Employees
N/A
N/A
Industry
Building Materials
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.6M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
AEHL
LYRA
Price
$0.94
$1.71
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
2.9M
129.9K
Earning Date
03-10-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$98,773,000.00
$600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$93.90
P/E Ratio
N/A
N/A
Revenue Growth
36.99
N/A
52 Week Low
$1.01
$1.63
52 Week High
$8.42
$37.50

Technical Indicators

Market Signals
Indicator
AEHL
LYRA
Relative Strength Index (RSI) 33.44 28.60
Support Level $1.17 $1.63
Resistance Level $1.46 $2.58
Average True Range (ATR) 0.16 0.30
MACD -0.01 -0.05
Stochastic Oscillator 12.43 3.90

Price Performance

Historical Comparison
AEHL
LYRA

About AEHL Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: